Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the progress of deviceful therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company's gene supply imminence to the rehabilitation of premature Parkinson's disease. The controlled, double blinded, 44 patient Phase 2 trial is investigating the safety and efficacy of a novel non-dopamine coming to restore motor task in Parkinson's patients who are sub-optimally responsive to in hand drug therapy...

More: - Read More